Company / FCF Margin
Adaptimmune Therapeutics PLC FCF Margin History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-41.6%
FY2024
5-year range
-1413.1% / 35.0%
FY2020-FY2024
Trend
+82.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FCF Margin has fluctuated over the past 9 years, ranging from -10169.3% in FY2019 to 35.0% in FY2021.
Based on SEC 10-K filings.
-41.6% in FY2024 with a 5-year CAGR of +10127.6%.
Improved from -630.9% to -41.6% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- -76.7pp
- 5-Year Change
- +10127.6pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2024, fcf margin increased 82.8% year-over-year.
- Peak fcf margin was recorded in FY2021.
- Lowest fcf margin in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -41.6% | +82.8% |
| FY2023 | -241.5% | +61.7% |
| FY2022 | -630.9% | -1899.9% |
| FY2021 | 35.0% | +102.5% |
| FY2020 | -1413.1% | +86.1% |
| FY2019 | -10169.3% | -5487.5% |
| FY2018 | -182.0% | +12.8% |
| FY2017 | -208.7% | +50.3% |
| FY2016 | -420.3% | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026